#Pharmaceutical Innovation
Explore articles tagged with Pharmaceutical Innovation
Two Bets on Complex Molecules, One Asset Light Model
HRV Pharma is planning a ₹150 crore investment in peptides and high-potency APIs through a dedicated peptide programme and a joint venture focused on specialised oncology molecules. Both initiatives follow the company's asset-light model, retaining intellectual property, regulatory assets and commercial rights while working with specialist manufacturing partners.
From Manufacturing Scale to Institutional Intelligence
The pharmaceutical industry's competitive edge is evolving from manufacturing capacity to institutional intelligence. Indian Pharma Post explores how HRV Pharma's RIKO uses seven years of proprietary operational data to assess risks, accelerate supplier qualification and support smarter pharmaceutical decision-making.
The Question That Built RIKO
Why do preventable pharmaceutical problems keep recurring years after key decisions are made? Digital Health News explores how HRV Pharma's RIKO uses seven years of operational workflows and ten federated reasoning models to identify risks earlier, accelerate supplier qualification and support faster pharmaceutical decision-making.
Meet RIKO, Built From Seven Years of Pharma Decisions
HRV Pharma has launched RIKO, an AI-native pharmaceutical operating system built on more than seven years of industry decisions. Drawing on insights from a network of 50+ FDA and EU GMP certified partners and customers across 55 countries, RIKO brings together AI-driven reasoning to support pharmaceutical sourcing, risk assessment and supplier qualification.